comparemela.com
Latest Breaking News On - Liean schenck - Page 1 : comparemela.com
Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights
INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease, completed enrollment in February 2023 Topline data expected in the third quarter of 2023 Cash, cash. | March 27, 2023
United-states
Daniel-oconnell
Derek-meisner
Alex-braun
Derrell-porter
Liean-schenck
Atara-biotherapeutics-inc
Acumen-pharmaceuticals-inc
Amgen
Clinical-development
Company-phase
Exchange-commission
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2022 Earnings Call Transcript
ABOS earnings call for the period ending June 30, 2022.
San-diego
California
United-states
Russia
Ukraine
Liean-schenck
Matt-zuga
John-woolford
Eli-lilly
Paul-matteis
Geoff-meacham
America-merrill-lynch
vimarsana © 2020. All Rights Reserved.